369 results on '"Gomez-Reino, Juan J"'
Search Results
2. Update of the position paper of the Spanish Society of Rheumatology on biosimilar drugs
3. Actualización del Documento de posicionamiento de la Sociedad Española de Reumatología sobre fármacos biosimilares
4. Chemical exposure-induced systemic fibrosing disorders: Novel insights into systemic sclerosis etiology and pathogenesis
5. Risk/benefit management in the infectious phase in systemic autoimmune rheumatic diseases
6. Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial
7. Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: Systematic review, meta-analysis, and network meta-analysis
8. Efficacy and Safety of Golimumab as Add-on Therapy to Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis: Results of the GO-MORE Study in Spain
9. Eficacia y seguridad de golimumab añadido a fármacos antirreumáticos modificadores de la enfermedad en artritis reumatoide. Resultados del estudio GO-MORE en España
10. New drugs from ancient natural foods. Oleocanthal, the natural occurring spicy compound of olive oil: a brief history
11. Impact of treatment with TNF antagonists on total cholesterol in patients with ankylosing spondylitis and psoriatic arthritis
12. Adipokines, Molecular Players at the Crossroad Between Inflammation and Oxidative Stress: Role in Arthropathies
13. Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis
14. Discovery of serum proteomic biomarkers for prediction of response to infliximab (a monoclonal anti-TNF antibody) treatment in rheumatoid arthritis: An exploratory analysis
15. Further evidence for the anti-inflammatory activity of oleocanthal: Inhibition of MIP-1α and IL-6 in J774 macrophages and in ATDC5 chondrocytes
16. Predictors of treatment failure and mortality in native septic arthritis
17. Efficacy and Safety of TNF Antagonists in Sarcoidosis: Data from the Spanish Registry of Biologics BIOBADASER and a Systematic Review
18. Demyelinating Disease in Patients Treated with TNF Antagonists in Rheumatology: Data from BIOBADASER, a Pharmacovigilance Database, and a Systematic Review
19. Cancer in Patients with Rheumatic Diseases Exposed to TNF Antagonists
20. Demyelinating Disease in Patients Treated with TNF Antagonists in Rheumatology: Data from BIOBADASER, a Pharmacovigilance Database, and a Systematic Review
21. Observational study of optimization of biologic therapies in rheumatoid arthritis: a single-centre experience
22. THERAPY: The NICE position on indications for biologics and biosimilars
23. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force
24. Las adipocinas: mediadores emergentes de la respuesta inmune y de la inflamación
25. Adipokines as novel modulators of lipid metabolism
26. Analysis of Infections and All-Cause Mortality in Phase II, Phase III, and Long-Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis
27. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies
28. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
29. Maintenance therapy of lupus nephritis with mycophenolate or azathioprine: systematic review and meta-analysis
30. Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis
31. Chapter 9 - Risk/benefit management in the infectious phase in systemic autoimmune rheumatic diseases
32. Impact of baseline body mass index on the efficacy and safety of tofacitinib in patients with psoriatic arthritis
33. Adipokines and Systemic Rheumatic Diseases: Linking Inflammation, Immunity and Metabolism
34. Tumour necrosis factor antagonist and tuberculosis in patients with rheumatoid arthritis: An Asian perspective
35. Reply
36. Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab
37. Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study
38. Association of anti–citrullinated vimentin and anti–citrullinated α-enolase antibodies with subsets of rheumatoid arthritis
39. Efficacy of different doses of rituximab for the treatment of RA: data From the CERERRA collaboration
40. Particular association of clinical and genetic features with autoimmunity to citrullinated α-enolase in rheumatoid arthritis
41. Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0
42. Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies
43. Long‐Term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials
44. CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial
45. Ghrelin in the Local Regulation of Endocrine Glands
46. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists
47. Rheumatoid arthritis does not share most of the newly identified systemic lupus erythematosus genetic factors
48. Large replication study and meta-analyses of DVWA as an osteoarthritis susceptibility locus in European and Asian populations
49. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study
50. A broad analysis of IL1 polymorphism and rheumatoid arthritis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.